We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone treatment in MS. This underscores the need for only using mitoxantrone in severe treatment-unresponsive cases of MS. Multiple Sclerosis 2008; 14: 272—273. http://msj.sagepub.com
Brassat D., Recher C., Waubant E., Le Page E., Rigal-Huquet F., Laurent G. et al. Therapy-related myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology2002; 59: 954—5.
Cordioli C., Cattaneo C., Rossi G.Analysis of incidence, risk factors and prognoiss of acute promyelocytic leukaemia related to mitoxantrone therapy in multiple sclerosis patients. Neurology2007; 68(Suppl 1): A276.
4.
Rivera V., Al-Sabbagh A., Bennett R., Coyle P., Mikol D., Panitch H. et al. Ongoing Evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: The RENEW Study. Neurology2007; 68(Suppl 1): A275.
5.
Morrissey SP , Le Page E., Edan G.Mitoxantrone in the treatment of multiple sclerosis. Int MS J2005; 12: 74—87.
6.
Fox E., Al-Sabbagh A., Bennett R., Sadiq SASafety and tolerability of Novantrone in clinical practice: status report from the registry to evaluate novantrone effects in worsening MS (RENEW) study . Neurology2005; 64(Suppl I): A394.
7.
Douglas JR, Robert H.Review of mitoxantrone in the treatment of multiple sclerosis. Neurology2004; 63: S19—S24.
8.
Hartung HP, Gonsette R., Koniq N., Kwiecinski G., Guseo A., Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet2002; 360: 2018—25.
9.
Kerr J., Eisenberg E., Sadiq S.Mitoxantrone therapy-associated menstrual dysfunction in patients with multiple sclerosis. Neurology2007; 68(Suppl 1): A275.
